The effect of PD-L1 testing on the cost-effectiveness and economic impact of immune checkpoint inhibitors for the second-line treatment of NSCLC

Affiliations

¹ Doctoral Grade Fellowship, Clinical Oncology Sector, Faculdade de Medicina do ABC, Santo André, Brazil.
² Faculty of Medicine, Monash University, Mildura, Australia.
³ Clinical Oncology Sector, Honor Health Scottsdale, Scottsdale, USA.
⁴ Clinical Oncology Sector, Universidade Federal de São Paulo, São Paulo, Brazil.
⁵ Clinical Oncology Sector, Universidade do Algarve, Faro, Portugal.
⁶ Clinical Oncology Sector at the University of Miami, Miami, USA.

Free article

Published Erratum

P N Aguiar Jr et al. Ann Oncol. 2018.

Free article

. 2018 Apr 1;29(4):1078.

doi: 10.1093/annonc/mdx478.

¹ Doctoral Grade Fellowship, Clinical Oncology Sector, Faculdade de Medicina do ABC, Santo André, Brazil.
² Faculty of Medicine, Monash University, Mildura, Australia.
³ Clinical Oncology Sector, Honor Health Scottsdale, Scottsdale, USA.
⁴ Clinical Oncology Sector, Universidade Federal de São Paulo, São Paulo, Brazil.
⁵ Clinical Oncology Sector, Universidade do Algarve, Faro, Portugal.
⁶ Clinical Oncology Sector at the University of Miami, Miami, USA.

No abstract available

Erratum for

The effect of PD-L1 testing on the cost-effectiveness and economic impact of immune checkpoint inhibitors for the second-line treatment of NSCLC.
Aguiar PN Jr, Perry LA, Penny-Dimri J, Babiker H, Tadokoro H, de Mello RA, Lopes GL Jr. Aguiar PN Jr, et al. Ann Oncol. 2017 Sep 1;28(9):2256-2263. doi: 10.1093/annonc/mdx305. Ann Oncol. 2017. PMID: 28633409